Loading…

Clinical predictors of therapeutic response to antipsychotics in schizophrenia

The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affe...

Full description

Saved in:
Bibliographic Details
Published in:Dialogues in clinical neuroscience 2014-12, Vol.16 (4), p.505-524
Main Authors: Carbon, Maren, Correll, Christoph U.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3
cites cdi_FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3
container_end_page 524
container_issue 4
container_start_page 505
container_title Dialogues in clinical neuroscience
container_volume 16
creator Carbon, Maren
Correll, Christoph U.
description The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affect modifiable risk factors, or use nonmodifiable factors to parse patients into therapeutically meaningful subgroups. Most clinical outcome predictors are nonspecific and/or nonmodifiable. Nonmodifiable predictors for poor odds of remission include male sex, younger age at disease onset, poor premorbid adjustment, and severe baseline psychopathology. Modifiable risk factors for poor therapeutic outcomes that clinicians can act upon include longer duration of untreated illness, nonadherence to antipsychotics, comorbidities (especially substance-use disorders), lack of early antipsychotic response, and lack of improvement with non-clozapine antipsychotics, predicting clozapine response. It is hoped that this limited capacity for prediction will improve as pathophysiological understanding increases and/or new treatments for specific aspects of schizophrenia become available.
doi_str_mv 10.31887/DCNS.2014.16.4/mcarbon
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_25733955</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1660655813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3</originalsourceid><addsrcrecordid>eNqFUc9P2zAUtqahwdj-Bchxl7Z2EjvxBWkrbExCcICdLeflhRgldrBdUPfXz6ylKicutqXv13v-CDlldF6wuq4W58vr23lOWTlnYl4uRtC-cfYDOWKS1zMuhfy49z4kn0N4oJSLJPlEDnNeFYXk_IhcLwdjDeghmzy2BqLzIXNdFnv0esJVNJB5DJOzAbPoMm2jmcIaepeQkBmbBejNXzf1Hq3RX8hBp4eAX7f3Mfnz8-JueTm7uvn1e_n9agaCsjhrRQOypiUw3tCqrrBNS7F0yIpTqOuixQa7jomW5aBZo1FUnaa5RGBtLqE4Jmcb32nVjNgC2uj1oCZvRu3Xymmj3iLW9OrePamyKITMaTL4tjXw7nGFIarRBMBh0BbdKigmBBWc16xI1GpDBe9C8NjtYhhV_9tQL22olzaSTpVq20ZSnuxPudO9fn8i_NgQjO2cH_Wz80Orol4PzndeWzAhJbyT8g9LaaMw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1660655813</pqid></control><display><type>article</type><title>Clinical predictors of therapeutic response to antipsychotics in schizophrenia</title><source>PubMed (Medline)</source><source>Taylor &amp; Francis (Open access)</source><creator>Carbon, Maren ; Correll, Christoph U.</creator><creatorcontrib>Carbon, Maren ; Correll, Christoph U.</creatorcontrib><description>The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affect modifiable risk factors, or use nonmodifiable factors to parse patients into therapeutically meaningful subgroups. Most clinical outcome predictors are nonspecific and/or nonmodifiable. Nonmodifiable predictors for poor odds of remission include male sex, younger age at disease onset, poor premorbid adjustment, and severe baseline psychopathology. Modifiable risk factors for poor therapeutic outcomes that clinicians can act upon include longer duration of untreated illness, nonadherence to antipsychotics, comorbidities (especially substance-use disorders), lack of early antipsychotic response, and lack of improvement with non-clozapine antipsychotics, predicting clozapine response. It is hoped that this limited capacity for prediction will improve as pathophysiological understanding increases and/or new treatments for specific aspects of schizophrenia become available.</description><identifier>ISSN: 1958-5969</identifier><identifier>ISSN: 1294-8322</identifier><identifier>EISSN: 1958-5969</identifier><identifier>DOI: 10.31887/DCNS.2014.16.4/mcarbon</identifier><identifier>PMID: 25733955</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Antipsychotic Agents - therapeutic use ; association ; Clinical Research ; Humans ; marker ; predictor ; psychosis ; remission ; response ; Risk Factors ; schizophrenia ; Schizophrenia - drug therapy ; Schizophrenic Psychology</subject><ispartof>Dialogues in clinical neuroscience, 2014-12, Vol.16 (4), p.505-524</ispartof><rights>Copyright: © 2014 Institut la Conférence Hippocrate - Servier Research Group 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3</citedby><cites>FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336920/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336920/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27502,27924,27925,53791,53793,59143,59144</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25733955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carbon, Maren</creatorcontrib><creatorcontrib>Correll, Christoph U.</creatorcontrib><title>Clinical predictors of therapeutic response to antipsychotics in schizophrenia</title><title>Dialogues in clinical neuroscience</title><addtitle>Dialogues Clin Neurosci</addtitle><description>The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affect modifiable risk factors, or use nonmodifiable factors to parse patients into therapeutically meaningful subgroups. Most clinical outcome predictors are nonspecific and/or nonmodifiable. Nonmodifiable predictors for poor odds of remission include male sex, younger age at disease onset, poor premorbid adjustment, and severe baseline psychopathology. Modifiable risk factors for poor therapeutic outcomes that clinicians can act upon include longer duration of untreated illness, nonadherence to antipsychotics, comorbidities (especially substance-use disorders), lack of early antipsychotic response, and lack of improvement with non-clozapine antipsychotics, predicting clozapine response. It is hoped that this limited capacity for prediction will improve as pathophysiological understanding increases and/or new treatments for specific aspects of schizophrenia become available.</description><subject>Antipsychotic Agents - therapeutic use</subject><subject>association</subject><subject>Clinical Research</subject><subject>Humans</subject><subject>marker</subject><subject>predictor</subject><subject>psychosis</subject><subject>remission</subject><subject>response</subject><subject>Risk Factors</subject><subject>schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><issn>1958-5969</issn><issn>1294-8322</issn><issn>1958-5969</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNqFUc9P2zAUtqahwdj-Bchxl7Z2EjvxBWkrbExCcICdLeflhRgldrBdUPfXz6ylKicutqXv13v-CDlldF6wuq4W58vr23lOWTlnYl4uRtC-cfYDOWKS1zMuhfy49z4kn0N4oJSLJPlEDnNeFYXk_IhcLwdjDeghmzy2BqLzIXNdFnv0esJVNJB5DJOzAbPoMm2jmcIaepeQkBmbBejNXzf1Hq3RX8hBp4eAX7f3Mfnz8-JueTm7uvn1e_n9agaCsjhrRQOypiUw3tCqrrBNS7F0yIpTqOuixQa7jomW5aBZo1FUnaa5RGBtLqE4Jmcb32nVjNgC2uj1oCZvRu3Xymmj3iLW9OrePamyKITMaTL4tjXw7nGFIarRBMBh0BbdKigmBBWc16xI1GpDBe9C8NjtYhhV_9tQL22olzaSTpVq20ZSnuxPudO9fn8i_NgQjO2cH_Wz80Orol4PzndeWzAhJbyT8g9LaaMw</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Carbon, Maren</creator><creator>Correll, Christoph U.</creator><general>Taylor &amp; Francis</general><general>Les Laboratoires Servier</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20141201</creationdate><title>Clinical predictors of therapeutic response to antipsychotics in schizophrenia</title><author>Carbon, Maren ; Correll, Christoph U.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antipsychotic Agents - therapeutic use</topic><topic>association</topic><topic>Clinical Research</topic><topic>Humans</topic><topic>marker</topic><topic>predictor</topic><topic>psychosis</topic><topic>remission</topic><topic>response</topic><topic>Risk Factors</topic><topic>schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><toplevel>online_resources</toplevel><creatorcontrib>Carbon, Maren</creatorcontrib><creatorcontrib>Correll, Christoph U.</creatorcontrib><collection>Taylor &amp; Francis (Open access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Dialogues in clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carbon, Maren</au><au>Correll, Christoph U.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical predictors of therapeutic response to antipsychotics in schizophrenia</atitle><jtitle>Dialogues in clinical neuroscience</jtitle><addtitle>Dialogues Clin Neurosci</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>16</volume><issue>4</issue><spage>505</spage><epage>524</epage><pages>505-524</pages><issn>1958-5969</issn><issn>1294-8322</issn><eissn>1958-5969</eissn><abstract>The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affect modifiable risk factors, or use nonmodifiable factors to parse patients into therapeutically meaningful subgroups. Most clinical outcome predictors are nonspecific and/or nonmodifiable. Nonmodifiable predictors for poor odds of remission include male sex, younger age at disease onset, poor premorbid adjustment, and severe baseline psychopathology. Modifiable risk factors for poor therapeutic outcomes that clinicians can act upon include longer duration of untreated illness, nonadherence to antipsychotics, comorbidities (especially substance-use disorders), lack of early antipsychotic response, and lack of improvement with non-clozapine antipsychotics, predicting clozapine response. It is hoped that this limited capacity for prediction will improve as pathophysiological understanding increases and/or new treatments for specific aspects of schizophrenia become available.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>25733955</pmid><doi>10.31887/DCNS.2014.16.4/mcarbon</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1958-5969
ispartof Dialogues in clinical neuroscience, 2014-12, Vol.16 (4), p.505-524
issn 1958-5969
1294-8322
1958-5969
language eng
recordid cdi_pubmed_primary_25733955
source PubMed (Medline); Taylor & Francis (Open access)
subjects Antipsychotic Agents - therapeutic use
association
Clinical Research
Humans
marker
predictor
psychosis
remission
response
Risk Factors
schizophrenia
Schizophrenia - drug therapy
Schizophrenic Psychology
title Clinical predictors of therapeutic response to antipsychotics in schizophrenia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A43%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20predictors%20of%20therapeutic%20response%20to%20antipsychotics%20in%20schizophrenia&rft.jtitle=Dialogues%20in%20clinical%20neuroscience&rft.au=Carbon,%20Maren&rft.date=2014-12-01&rft.volume=16&rft.issue=4&rft.spage=505&rft.epage=524&rft.pages=505-524&rft.issn=1958-5969&rft.eissn=1958-5969&rft_id=info:doi/10.31887/DCNS.2014.16.4/mcarbon&rft_dat=%3Cproquest_pubme%3E1660655813%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1660655813&rft_id=info:pmid/25733955&rfr_iscdi=true